CureVac - Ingmar Hoerr, CEO
Added on 29 Mar 2017
Watched
3,315
times
CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimised and formulated. Since 2000 the company develops novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive®. CureVac has successfully established the first GMP (good manufacturing practice) facility worldwide for the manufacture of RNA and mRNA and has pioneered mRNA-based drugs in clinical studies.
コメント
あなたのアカウントにはアバターがありません
コメントの投稿を続行するには、一時的なアバターを選択してください:
Confirm
誤りがあります、もう一度やり直してください。
Or
Y8アカウントをアップロード
取り消し